trimetazidine has been researched along with Liver Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, W; Qian, J; Tang, L; Yang, L; Zhang, S; Zhou, D | 1 |
| Campi, S; Catapano, AL; Faggiotto, A; Redaelli, L; Zoppo, A | 1 |
2 other study(ies) available for trimetazidine and Liver Cirrhosis
| Article | Year |
|---|---|
Trimetazidine inhibits liver fibrosis and hepatic stellate cell proliferation and blocks transforming growth factor-β (TGFβ)/Smad signaling
Topics: Animals; Cell Proliferation; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Mice; Smad Proteins; Transforming Growth Factor beta; Transforming Growth Factors; Trimetazidine | 2022 |
Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient.
Topics: Humans; Hypertension; Immunosuppressive Agents; Kidney Diseases; Liver Cirrhosis; Liver Transplantation; Tacrolimus; Trimetazidine; Vasodilator Agents | 1999 |